恩替卡韦治疗HBV相关性肝衰竭随机对照试验的Meta分析  

Effect of enticavir on survival of patients with HBV-related liver failure: A Meta-analysis

作　　者：马莎莎[1] 吴继周[1] 宁秋悦[1] 钟大妮[1] 吴健林[1] 

机构地区：[1]广西医科大学第一附属医院感染性疾病科,广西壮族自治区南宁市530021

出　　处：《世界华人消化杂志》2013年第25期2594-2600,共7页World Chinese Journal of Digestology

摘　　要：目的:系统评价恩替卡韦治疗乙型肝炎病毒相关性肝衰竭的疗效.方法:检索2005-01/2013-04有关在常规内科治疗基础上使用恩替卡韦后对患者生存率及DNA转阴率影响的随机对照试验,应用Meta分析的方法以比值比(odds ratio,OR)为效应量进行合并分析.结果:共纳入18篇RCT,生存率的合并效应量OR值及95%CI:2.17(95%CI:1.63-2.89),HBVDNA转阴率的OR值的合并效应量及95%CI:20.32(95%CI:8.09-51.04).结论:与内科常规治疗比较,加用恩替卡韦可显著抑制HBV的复制,明显提高生存率.AIM： To evaluate the effect of entecavir on survival of patients with HBV-related liver failure. METHODS： This meta-analysis collected the randomized control trails that used entecavir to treat liver failure induced by hepatitis B virus from January 2005 to April 2013. All these clinical trials were carried out by comparing entecavir treatment with routine medical treatment for liver failure. Odds ratio （OR） was used to evaluate the effect of entecavir on survival and reduction in HBV-DNA levels in patients with HBV-related liver failure. RESULTS： A total of 18 studies were included. OR for the survival rate was 2.17 （95% CI： 1.63-2.89） and OR for reduction in HBV-DNA levels was 20.32 （95%CI： 8.09-51.04）. CONCLUSION： Routine medical treatment in combination with entecavir is more effective than routine medical treatment alone in improving survival and inhibiting HBV replication in patients with HBV-associated liver failure.

关 键 词：恩替卡韦 HBV相关性肝衰竭 随机对照试验 META分析 

分 类 号：R512.62[医药卫生—内科学] R575.3[医药卫生—临床医学]